Further, a study on patients with inborn mutations in their STAT1 genes, and of the potential cross-regulation mechanisms between STAT1 and STAT3, may provide novel therapeutic strategies against colon cancer. This evidence concerns the gene STAT3 and malignant colon neoplasm.